TransMedics Group, Inc. (TMDX)
NEUTRALFundamental
67
मूल्य
$93.27
मार्केट कैप
$3.26B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
बैलेंस शीट और तरलता
राजस्व
$668M
पिछले 12 महीने (30/6/2026 तक)
शुद्ध आय
$152M
पिछले 12 महीने (30/6/2026 तक)
Free Cash Flow
$134M
कुल इक्विटी
$473M
कुल देनदारियाँ
$595M
Current Ratio
6.62
Interest Coverage
3.84
Debt/EBITDA
6.39
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$78.14
वर्तमान मूल्य
$93.27
Margin of Safety
-19.4%
Fair Value सीमा
$50.79 - $105.49
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
24.25
ROE
40.2%
P/B Ratio
6.26
P/FCF
41.06
Gross Margin
58.7%
ROIC
4.7%
लाभप्रदता Radar
Value Creation (Economic Moat)
ROIC
4.7%
WACC
12.3%
ROIC − WACC
-7.6 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental विश्लेषण मानदंड
पास (17)
- EPS shows upward trend
- Price CAGR 25.79%
- Gross Margin 58.7%
- Debt/Equity ratio
- Operating Margin 12.2%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- ROE 33.0%
- Revenue Growth 5Y 88.2%
- Analyst Consensus 68% Buy
- Earnings Surprise avg 14.1%
- Earnings Quality (OCF/NI) 0.96
- Net Margin Trend 22.7% vs 13.5%
- Piotroski F-Score 7/9
फेल (8)
- ROIC 4.7%
- P/FCF 41.06
- P/B Ratio 6.26
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- DCF valuation (Overvalued)
- Share Dilution 11.3%
अनुपलब्ध (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
मजबूत वित्तीय स्वास्थ्य
Earnings गुणवत्ता
मध्यम: मुनाफे और नकदी के बीच कुछ अंतर
शेयर Dilution
नए शेयर जारी कर रही है, स्वामित्व को कम कर रही है
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Dr. Waleed H. Hassanein M.D. | Founder, President, CEO & Director | 57 |
| Mr. Gerardo Hernandez | CFO & Treasurer | 54 |
| Mr. Nicholas Corcoran | Senior Vice President of Supply Chain & Operations | 43 |
| Dr. Tamer I. Khayal M.D. | Senior Vice President of International | 56 |
| Mr. Anil Ranganath | Advisor | 43 |
| Mr. Matthew Forsyth | Senior VP, General Counsel & Corporate Secretary | - |
| Ms. Miriam C. Provost Ph.D. | Vice President of Global Regulatory Affairs | 64 |
Audit जोखिम
10
बोर्ड जोखिम
3
मुआवजा जोखिम
7
शेयरधारक अधिकार जोखिम
3
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
Latest News
Recent headlines for TMDX, sourced from Markets Gazette.
- 3/8/2026POSITIVETransMedics Stock Is Up 104% Over the Last Year: Is It Too Late to Buy for 2026?
TransMedics Group Inc. has demonstrated remarkable growth, with its stock price surging 104% over the past year. The company is recognized for its innovative approach to revolutionizing the organ transplant industry. Despite this impressive performance, market sentiment remains divided, with some analysts labeling the stock as 'overvalued.' Investors are now contemplating whether the significant gains made thus far leave room for further appreciation by 2026, balancing the company's disruptive potential against current valuation concerns.
- 2/28/2026POSITIVEGot $5,000? TransMedics Could Be a High‑Tech Organ Transplant Moonshot
TransMedics Group, Inc., a mid-cap healthcare specialist, is drawing investor attention as a potential 'moonshot' in the high-tech organ transplant sector. The company, focused on advanced solutions for organ preservation and transport, is seen as a significant investment opportunity for those seeking growth in innovative medical fields. Analysts suggest that with an initial capital of around $5,000, investors might consider a deeper look into this company, given its prominent position in a market segment with high expansion potential and technological innovation. Its technology could revolutionize current practices, offering attractive long-term return prospects.
via Markets Gazette